Actuate Therapeutics, Inc. Common stock

NASDAQ ACTU
$8.24 -0.48 -5.50%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 22.5 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
132.00M
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
128.11M
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
-
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
19.50M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
3.52 %

Upcoming events Actuate Therapeutics, Inc. Common stock

All events
No upcoming events scheduled

Stock chart Actuate Therapeutics, Inc. Common stock

Stock analysis Actuate Therapeutics, Inc. Common stock

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-5.22 -1.30
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
639.69 1.15
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-5.12 -0.75
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
0.16 0.42
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
497.40 -50.00

Price change Actuate Therapeutics, Inc. Common stock per year

5.80$ 11.00$
Min Max

Summary analysis Actuate Therapeutics, Inc. Common stock

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Actuate Therapeutics, Inc. Common stock

Revenue and net income Actuate Therapeutics, Inc. Common stock

All parameters

About company Actuate Therapeutics, Inc. Common stock

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. Its lead product candidate, Elraglusib Injection, is a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. The company also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. It has license agreements with the University of Illinois-Chicago and Northwestern University for the use of GSK-3B inhibitor. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is based in Fort Worth, Texas.
Address:
1751 River Run, Fort Worth, TX, United States, 76107
Company name: Actuate Therapeutics, Inc. Common stock
Issuer ticker: ACTU
ISIN: US0050831009
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2024-08-13
Sector: Healthcare
Industry: Biotechnology
Site: https://actuatetherapeutics.com